DAACS
DEAD

Serial Number

87519680

Owner

Axcella Health Inc.

Attorney

Christina M. Licursi, Esq.

Filing Date

Jul 7, 2017

Add to watchlist:

No watchlists yet
View on USPTO

DAACS Trademark

Serial Number: 87519680

DAACS is a trademark filed by Axcella Health Inc. on July 7, 2017. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Axcella Health Inc. (15 trademarks)

Third Floor
Cambridge, MA 02139

Entity Type: 03

Trademark Details

Filing Date

July 7, 2017

Registration Date

Not Registered

Published for Opposition

December 5, 2017

Goods & Services

pharmaceutical preparations and agents for the treatment or prevention of diseases, disorders and conditions associated with amino acid dysregulation, disruption of cellular homeostasis, protein energy dysfunction, the muscular system, the skeletal system, the cardiovascular system, the hematological system, the respiratory system, the hepatobiliary system, the gastrointestinal system, the endocrine system, the urinary system, the reproductive system, the immune system, the integumentary system, muscle, bones, joints, and whole body movement; proteins, polypeptides, peptides, amino acids, and small molecules being a featured component of pharmaceutical preparations for the treatment or prevention of diseases, disorders and conditions associated with amino acid dysregulation, disruption of cellular homeostasis, protein energy dysfunction, the muscular system, the skeletal system, the cardiovascular system, the hematological system, the respiratory system, the hepatobiliary system, the gastrointestinal system, the endocrine system, the urinary system, the reproductive system, the immune system, the integumentary system, muscle, bones, joints, and whole body movement; medicines, namely, proteins, biomolecules in the nature of polypeptides and peptides, amino acids, and small molecules in the nature of organic compounds and amino acid metabolites for the treatment or prevention of diseases, disorders and conditions associated with amino acid dysregulation, disruption of cellular homeostasis, protein energy dysfunction, the muscular system, the skeletal system, the cardiovascular system, the hematological system, the respiratory system, the hepatobiliary system, the gastrointestinal system, the endocrine system, the urinary system, the reproductive system, the immune system, the integumentary system, muscle, bones, joints, and whole body movement; medical foods, namely, food that is intended for the specific dietary management of a disease or condition; nutraceuticals for treating or restoring health in patients with diseases, disorders and conditions associated with amino acid dysregulation, disruption of cellular homeostasis, protein energy dysfunction, the muscular system, the skeletal system, the cardiovascular system, the hematological system, the respiratory system, the hepatobiliary system, the gastrointestinal system, the endocrine system, the urinary system, the reproductive system, the immune system, the integumentary system, muscle, bones, joints, and whole body movement; dietary and nutritional supplements

Chemical and biochemical compounds, proteins, polypeptides and peptides, amino acids, vitamins, minerals, nutrients and nutritive products, and pharmaceutical excipients for use in scientific and medical research; chemical and biochemical compounds, proteins, polypeptides and peptides, amino acids, vitamins, minerals, and nutrients and nutritive products for use in the manufacture of beverages, food products and food supplements for human and non-human use; chemical and biochemical compounds, proteins, polypeptides and peptides, amino acids, vitamins, minerals, nutrients and nutritive products, and pharmaceutical excipients for use in the manufacture of pharmaceutical preparations, medicines, medical foods, nutraceuticals, and dietary and nutritional foods and supplements; chemical and biochemical compounds, proteins, polypeptides, peptides, amino acids, vitamins, minerals, and nutrients and nutritive products being an ingredient in the manufacture of pharmaceutical preparations for the treatment or prevention of diseases, disorders and conditions associated with amino acid dysregulation, disruption of cellular homeostasis, protein energy dysfunction, the muscular system, the skeletal system, the cardiovascular system, the central nervous system, the hematological system, the respiratory system, the hepatobiliary system, the gastrointestinal system, the endocrine system, the urinary system, the reproductive system, the immune system, the integumentary system, and muscle, bones, joints, and whole body movement; chemical and biochemical compounds, proteins, polypeptides, peptides, amino acids, vitamins, minerals, and nutrients and nutritive products being an ingredient in the manufacture of pharmaceutical preparations for the treatment or prevention of muscle loss, metabolic conditions and diseases, gastrointestinal conditions and diseases, neurological conditions and diseases, cancer, osteoporosis, inflammatory conditions and diseases, genetic conditions and diseases, muscle diseases and disorders, hepatic conditions and diseases, fibrosis, malnutrition, atrophic diseases and conditions, epilepsy, sarcopenia, myopathies, neuropathies, neurodegenerative diseases, traumatic brain injury, concussion, movement disorders, dystrophies, anemias, and orphan diseases; chemical and biochemical compounds, proteins, polypeptides and peptides, amino acids, vitamins, minerals, nutrients and nutritive products, and pharmaceutical excipients for in vitro medical research and in vivo scientific research

Filing History

ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Sep 4, 2018 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Sep 3, 2018 ABN6
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jan 30, 2018 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 5, 2017 NPUB
PUBLISHED FOR OPPOSITION
Dec 5, 2017 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 15, 2017 NONP
ASSIGNED TO LIE
Oct 27, 2017 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 11, 2017 CNSA
EXAMINER'S AMENDMENT ENTERED
Oct 11, 2017 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Oct 11, 2017 GNEN
EXAMINERS AMENDMENT E-MAILED
Oct 11, 2017 GNEA
EXAMINERS AMENDMENT -WRITTEN
Oct 11, 2017 CNEA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 6, 2017 GNRN
NON-FINAL ACTION E-MAILED
Oct 6, 2017 GNRT
NON-FINAL ACTION WRITTEN
Oct 6, 2017 CNRT
ASSIGNED TO EXAMINER
Oct 3, 2017 DOCK
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Sep 20, 2017 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Sep 20, 2017 REAP
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 14, 2017 NWOS
NEW APPLICATION ENTERED
Jul 11, 2017 NWAP